The transitive property across randomized controlled trials: If B is better than A, and C is better than B, will C be better than A?;La propiedad transitiva en los ensayos clínicos controlados: si B es mejor que A y C es mejor que B, ¿c será mejor que A?

Revista Espanola de Cardiologia

Volumn 67, Issue 8, 2014, Pages 597-602

  Catalá López, Ferrán ^a,b   Hutton, Brian ^c   Moher, David ^c  

^a Division de Farmacoepidemiologia y Farmacovigilancia   (Spain)

^b Fundacion Instituto de Investigacion en Servicios de Salud   (Spain)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CARDIOVASCULAR DISEASES; HUMAN;

CARDIOVASCULAR DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84904735545     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2013.11.016     Document Type: Article

References (16)

1. J.P. Ioannidis Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses CMAJ 181 2009 488 493
2. E.J. Mills, J.P. Ioannidis, K. Thorlund, H.J. Schünemann, M.A. Puhan, and G.H. Guyatt How to use an article reporting a multiple treatment comparison meta-analysis JAMA 308 2012 1246 1253
3. F. Catalá-López, and A. Tobías Síntesis de la evidencia clínica y metaanálisis en red con comparaciones indirectas Med Clin (Barc) 140 2013 182 187
4. S.G. Baker, and B.S. Kramer The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol 2 2002 13
5. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
6. S. Yusuf, K.K. Teo, J. Pogue, L. Dyal, I. Copland ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
7. S. Yusuf, K. Teo, C. Anderson, J. Pogue, L. Dyal Telmisartan Randomised AssessmeNt Study in, ACE., iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
8. S. Yusuf, H.C. Diener, R.L. Sacco, D. Cotton, S. Ounpuu, and W.A. Lawton et al. Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 2008 1225 1237
9. M. Szklo, and F.J. Nieto Epidemiología intermedia: conceptos y aplicaciones 2003 Díaz de Santos Madrid
10. A.S. Abdelhamid, Y.K. Loke, S. Parekh-Bhurke, Y.F. Chen, A. Sutton, and A. Eastwood et al. Use of indirect comparison methods in systematic reviews: a survey of Cochrane review authors Res Syn Meth 3 2012 71 79
11. ® (telmisartan) tablets. Silver Spring: U.S. FDA; 2009. Disponible en: http://www.fda.gov/
12. R. Vidal-Pérez, and J.R. González-Juanatey Implicaciones clínicas del programa ONTARGET en pacientes con cardiopatía isquémica crónica Rev Esp Cardiol Supl 8 2008 63E 72E
13. F. Catalá-López, and A. Tobías Metaanálisis de ensayos clínicos aleatorizados, heterogeneidad e intervalos de predicción Med Clin (Barc) 142 2014 270 274
14. J.A. Knottnerus, and P. Tugwell Heterogeneity and clinical reality J Clin Epidemiol 66 2013 809 811
15. G. Salanti, V. Marinho, and J.P. Higgins A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered J Clin Epidemiol 62 2009 857 864
16. B. Hutton, J. Tetzlaff, F. Yazdi, J. Thielman, S. Kanji, and D. Fergusson et al. Comparative effectiveness of monotherapies and combination therapies for patients with hypertension: protocol for a systematic review with network meta-analyses Syst Rev 2 2013 44